SCHEDULE: Bios Equity Partners Updates Lantern Pharma Stake

Bios Equity Partners and associated entities have filed an amendment to their Schedule 13D regarding their beneficial ownership in Lantern Pharma Inc.

Summary

• The filing represents Amendment No. 6 to the Schedule 13D originally filed on June 15, 2020.
• Reporting persons, including Bios Equity Partners, LP and associated entities, disclose their current beneficial ownership of Lantern Pharma Inc. common stock.
• The aggregate beneficial ownership for the primary reporting group (including Aaron G.L. Fletcher and Leslie W. Kreis) is 834,752 shares, representing 7.4% of the outstanding common stock.
• The percentage calculation is based on 11,254,697 outstanding shares as reported in the Issuer's Form 10-Q filed on March 16, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral regulatory filing that provides transparency regarding existing shareholdings without signaling a change in strategic direction or financial performance.

Positives

• Continued long-term investment interest from institutional stakeholders.
• Transparency in reporting beneficial ownership changes through regular SEC filings.

Negatives

• No specific negative operational or financial news disclosed in this ownership update.

Risks

• Concentration of ownership among a group of related investment entities.
• Potential for market volatility if significant shareholders decide to divest their positions.

Future Outlook

The filing does not provide forward-looking guidance regarding the Issuer's business operations, focusing strictly on the disclosure of beneficial ownership.

Industry Context

StockSavvy.ai notes that this filing is a standard regulatory disclosure regarding institutional ownership in the biotechnology sector, reflecting ongoing portfolio management by venture capital and private equity firms.

Comparison to Industry Standards

• The filing adheres to standard SEC requirements for beneficial ownership reporting (Schedule 13D) for entities holding over 5% of a public company's equity.
• The reporting structure is consistent with typical practices for private equity firms managing multiple fund vehicles.

Stakeholder Impact

• Shareholders should note the current concentration of ownership among the Bios Equity entities.
• No immediate impact on employees, customers, or suppliers is indicated.

Next Steps

• Continued monitoring of future SEC filings for any further changes in beneficial ownership.

Key Dates

Keywords

Lantern Pharma, Schedule 13D, Bios Equity Partners, Beneficial Ownership, Biotech Investment, SEC Filing